Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Core Viewpoint - Terns Pharmaceuticals is hosting an investor educational webinar on TERN-701, an investigational treatment for chronic myeloid leukemia (CML), ahead of data release expected in Q4 2025 [1][2]. Group 1: TERN-701 Overview - TERN-701 is a next-generation oral, allosteric BCR-ABL inhibitor targeting the ABL myristoyl pocket, currently evaluated for CML treatment [2][3]. - The CARDINAL Phase 1 clinical trial is assessing TERN-701's safety, tolerability, and efficacy in previously treated chronic phase CML patients [3]. Group 2: Clinical Trial Details - The dose escalation portion of the CARDINAL trial was completed in January 2025, with no dose limiting toxicities observed up to a maximum dose of 500 mg QD [3][4]. - The dose expansion phase began in April 2025, randomizing patients into two cohorts (320 mg or 500 mg QD) with up to 40 patients per arm [3]. - Efficacy and safety data from the Phase 1 trial are expected to be reported in Q4 2025, including the 6-month major molecular response achievement rate [3]. Group 3: Interim Data - Positive interim data from the dose escalation phase showed compelling molecular responses at the lowest dose in heavily pre-treated CML patients with high baseline BCR-ABL transcript levels [4]. - The trial demonstrated an encouraging safety profile with no dose limiting toxicities or treatment discontinuations across all cohorts [4]. Group 4: Company Background - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases, including oncology and obesity [5]. - The company's pipeline includes three clinical stage programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [5].